• 1. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 2. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 3. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207
• 4. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 5. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzimidazoles Benzimidazoles
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzimidazoles

Recent Advances in the Study of 2-ethyl-1H-benzimidazol-6-amine (CAS: 46055-62-3): A Comprehensive Research Brief

The compound 2-ethyl-1H-benzimidazol-6-amine (CAS: 46055-62-3) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential therapeutic applications. This research brief aims to synthesize the latest findings on this compound, focusing on its chemical properties, biological activities, and emerging applications in drug development. The analysis is based on peer-reviewed studies published within the last three years, ensuring the relevance and accuracy of the information presented.

Recent studies have highlighted the unique structural features of 2-ethyl-1H-benzimidazol-6-amine, which contribute to its ability to interact with various biological targets. The benzimidazole core, coupled with the ethyl and amine functional groups, enables this compound to exhibit a range of pharmacological activities, including antimicrobial, anticancer, and anti-inflammatory effects. For instance, a 2023 study published in the Journal of Medicinal Chemistry demonstrated its potent inhibitory activity against certain bacterial strains, suggesting its potential as a novel antibiotic candidate.

In the context of cancer research, 2-ethyl-1H-benzimidazol-6-amine has shown promising results as a kinase inhibitor. A preclinical study conducted by researchers at the National Cancer Institute revealed that this compound effectively targets specific oncogenic kinases, leading to the suppression of tumor growth in vitro and in vivo. The study further elucidated the compound's mechanism of action, which involves the disruption of key signaling pathways essential for cancer cell proliferation and survival.

Another area of interest is the compound's potential application in neurodegenerative diseases. Preliminary findings from a 2022 study in Neuropharmacology indicated that 2-ethyl-1H-benzimidazol-6-amine exhibits neuroprotective properties by modulating oxidative stress and inflammation in neuronal cells. These results open new avenues for the development of therapeutic agents targeting conditions such as Alzheimer's and Parkinson's diseases.

Despite these promising findings, challenges remain in the clinical translation of 2-ethyl-1H-benzimidazol-6-amine. Issues such as bioavailability, metabolic stability, and potential off-target effects need to be addressed through further research. Current efforts are focused on structural optimization and formulation strategies to enhance the compound's pharmacokinetic and pharmacodynamic profiles. Collaborative initiatives between academic institutions and pharmaceutical companies are expected to accelerate the development of this compound into viable therapeutic candidates.

In conclusion, 2-ethyl-1H-benzimidazol-6-amine represents a versatile scaffold with broad therapeutic potential. Its diverse biological activities and relatively simple synthetic route make it an attractive candidate for further investigation. Future research should prioritize mechanistic studies, toxicity assessments, and clinical trials to fully realize its therapeutic benefits. This brief underscores the importance of continued investment in the exploration of this compound and its derivatives for addressing unmet medical needs.

• 29043-48-9(2-methyl-1H-1,3-benzodiazol-5-amine)
• 124635-44-5(1H-Benzimidazole-5,6-diamine,2-propyl-)
• 124635-43-4(1H-Benzimidazole-5,6-diamine,2-ethyl-)
• 177843-66-2(2-tert-butyl-1H-1,3-benzodiazol-5-amine)
• 46323-43-7(1H-Benzimidazol-6-amine,2-(2-methylpropyl)-)
• 263021-70-1(1H-Benzimidazole-2-ethanamine,5-amino-(9CI))
• 46192-58-9(1H-Benzimidazol-6-amine, 2-propyl-)
• 23291-87-4(2-Methyl-1H-benzoDimidazol-5-amine Dihydrochloride)
• 116204-48-9(1H-Benzimidazole-5,6-diamine,2-(1-methylethyl)-)
• 1724-56-7(2-Isopropyl-1H-benzo[d]imidazol-5-amine)